WBI Investments LLC Purchases New Stake in Organon & Co. $OGN

Key Points

• WBI Investments LLC has invested approximately $946,000 in Organon & Co., acquiring 63,552 shares in the first quarter.
• Several institutional investors have modified their positions in Organon & Co., with BNP Paribas purchasing $2.44 million worth of shares.
• Organon & Co. recently reported earnings of $1.00 per share, outperforming the consensus estimate of $0.94, even as revenue showed a slight decline from the previous year.

WBI Investments LLC bought a new position in Organon & Co. (NYSE:OGN - Free Report) in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 63,552 shares of the company's stock, valued at approximately $946,000.

A number of other institutional investors and hedge funds have also recently made changes to their positions in the stock. SBI Securities Co. Ltd. lifted its holdings in shares of Organon & Co. by 17.6% in the first quarter. SBI Securities Co. Ltd. now owns 7,653 shares of the company's stock worth $114,000 after acquiring an additional 1,145 shares during the last quarter. Rafferty Asset Management LLC raised its holdings in Organon & Co. by 5.6% in the 4th quarter. Rafferty Asset Management LLC now owns 22,627 shares of the company's stock valued at $338,000 after buying an additional 1,194 shares during the last quarter. Handelsbanken Fonder AB raised its holdings in Organon & Co. by 1.5% in the 1st quarter. Handelsbanken Fonder AB now owns 81,565 shares of the company's stock valued at $1,215,000 after buying an additional 1,200 shares during the last quarter. Xponance Inc. raised its holdings in Organon & Co. by 15.2% in the 1st quarter. Xponance Inc. now owns 13,828 shares of the company's stock valued at $206,000 after buying an additional 1,823 shares during the last quarter. Finally, Brown Advisory Inc. raised its holdings in Organon & Co. by 6.5% in the 1st quarter. Brown Advisory Inc. now owns 30,174 shares of the company's stock valued at $449,000 after buying an additional 1,835 shares during the last quarter. Institutional investors own 77.43% of the company's stock.

Analyst Ratings Changes

Separately, BNP Paribas upgraded shares of Organon & Co. to a "strong-buy" rating in a report on Thursday, May 22nd. One equities research analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating and two have issued a Hold rating to the stock. According to data from MarketBeat, Organon & Co. currently has a consensus rating of "Moderate Buy" and a consensus price target of $17.33.

Organon & Co. Trading Up 1.1%

Shares of OGN stock traded up $0.12 during trading hours on Tuesday, hitting $10.52. 1,073,893 shares of the company were exchanged, compared to its average volume of 4,392,088. The firm has a market cap of $2.73 billion, a P/E ratio of 3.92, a P/E/G ratio of 0.97 and a beta of 0.60. Organon & Co. has a fifty-two week low of $8.01 and a fifty-two week high of $20.96. The company has a debt-to-equity ratio of 11.98, a quick ratio of 1.13 and a current ratio of 1.65. The company has a 50 day simple moving average of $9.65 and a two-hundred day simple moving average of $10.79.

Organon & Co. (NYSE:OGN - Get Free Report) last announced its quarterly earnings data on Tuesday, August 5th. The company reported $1.00 EPS for the quarter, topping the consensus estimate of $0.94 by $0.06. The company had revenue of $1.59 billion during the quarter, compared to the consensus estimate of $1.55 billion. Organon & Co. had a net margin of 11.15% and a return on equity of 163.88%. The company's quarterly revenue was down .8% on a year-over-year basis. During the same quarter last year, the firm posted $1.12 EPS. Organon & Co. has set its FY 2025 guidance at EPS. Equities analysts anticipate that Organon & Co. will post 3.68 EPS for the current year.

Organon & Co. Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Thursday, September 11th. Stockholders of record on Friday, August 15th were given a dividend of $0.02 per share. The ex-dividend date of this dividend was Friday, August 15th. This represents a $0.08 annualized dividend and a dividend yield of 0.8%. Organon & Co.'s dividend payout ratio (DPR) is 2.97%.

Organon & Co. Profile

Organon & Co is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women's health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.